EHA 2024 Hybrid Congress

The European Hematology Association (EHA) 2024 Congress was held June 13-16, 2024 in Madrid, Spain.

High circular RNA abundance is correlated with disease progression in patients with MDS.

Isolating CD34-positive samples from patients with MDS was better able to detect molecular relapse.

More patients treated with luspatercept had improvement or resolution of neutropenia and thrombocytopenia, she said.

At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.

Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.

The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.

The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.

Multivariable analysis in a phase II study linked the supplements to an overall survival benefit in patients.

Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.

A triplet for multiple myeloma has shown promising safety and efficacy in elderly patients ineligible for transplant.

Christophe Willekens, MD, compares standard dosing venetoclax for AML to seven-day dosing plus azacitidine.

Linvoseltamab achieved on ORR of 71% and a CR rate of 50% in patients with relapsed or refractory multiple myeloma.

Results from a new analysis reaffirm the initial findings of the global, phase III IMerge trial.

The 2024 Society of Hematologic Oncology (SOHO) Annual Meeting will take place September 4-7 in Houston, Texas.

Researchers construct a single MDS classification system which integrates the two major international systems.

The study was a noninterventional based on data collected through November 2023.

Dr. Manier tells of which new phase III data he finds especially exciting in myeloma care.

Dr. Sockel from University Hospital Carl Gustav Carus Dresden discusses recent progress and new directions in MDS management.

The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.

Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.